Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pefloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 1.00 |
| ▸ | HPGD | P15428 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 6/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 0.90 |
| ▸ | GAA | P10253 | 2/20 | 0.75 |
| ▸ | RAD52 | P43351 | 1/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.72 |
| ▸ | HTT | P42858 | 4/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | BRD4 | O60885 | 1/20 | 0.71 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.71 |
| ▸ | GLA | P06280 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pefloxacin SCHEMBL29594648 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| Pefloxacin SCHEMBL19514797 | 0.99 | KDM4E (0.98) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| Pefloxacin SCHEMBL27952963 | 0.99 | KDM4E (0.98) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| Pefloxacin SCHEMBL28251251 | 0.95 | DRD3 (1.00) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| Pefloxacin SCHEMBL34292 | 0.95 | DRD3 (1.00) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| Pefloxacin SCHEMBL29351730 | 0.95 | DRD3 (1.00) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| Pefloxacin SCHEMBL192462 | 0.94 | KDM4E (0.89) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| Pefloxacin SCHEMBL10911017 | 0.94 | DRD3 (0.98) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| Pefloxacin SCHEMBL28542234 | 0.94 | DRD3 (0.98) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| Pefloxacin SCHEMBL9800276 | 0.94 | DRD3 (0.98) | KDM4EALDH1A1HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1408 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12274830-B2 | Nitric oxide inhalation therapy for infants with bronchiolitis | BEYOND AIR LTD (IL) | 2025-04-15 | — | — | US | claimed |
| US-20240173512-A1 | METHODS FOR POTENTIATING ANTIMICROBIAL AGENTS | STREETERVILLE CAPITAL, LLC | 2024-05-30 | — | — | US | claimed |
| US-11890421-B2 | Methods for potentiating antimicrobial agents | BEYOND AIR LTD (IL) | 2024-02-06 | — | — | US | claimed |
| CN-112912386-B | Cell penetrating peptides based on influenza virus M2 proteins | 中国医学科学院基础医学研究所 | 2023-10-20 | — | — | CN | claimed |
| CN-115656122-A | Method for detecting antibiotics based on up-conversion nanoparticle-silk fibroin nanoprobe system | 浙江大学 | 2023-01-31 | — | — | CN | claimed |
| EP-4057813-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | New Life Crop Sciences LLC (US) | 2022-09-21 | — | — | EP | claimed |
| CN-114980736-A | Compositions and methods for treating citrus greening disease | 新生命作物科学有限责任公司 | 2022-08-30 | — | — | CN | claimed |
| US-20220169680-A1 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2022-06-02 | — | — | US | claimed |
| CN-111521712-B | Liquid chromatography analysis method for simultaneously determining contents of 3 sulfonamides and 4 quinolones | 重庆方通动物药业有限公司 | 2022-05-06 | — | — | CN | claimed |
| EP-3912989-A1 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | Institute of Basic Medical Sciences Chinese Academy of Medical Sciences (CN) | 2021-11-24 | — | — | EP | claimed |
| US-20060269485-A1 | Antibiotic kit and composition and uses thereof | FOAMIX LTD. (IL) | 2006-11-30 | — | — | US | claimed |
| CN-1826129-A | Methods and compositions relating to isoleucine boroproline compounds | POINT THERAPEUTICS INC (US) | 2006-08-30 | — | — | CN | claimed |
| CN-1814749-A | Instant pig semen diluent | XIE LAIAN (CN) | 2006-08-09 | — | — | CN | claimed |
| EP-1656018-A1 | EDIBLE FILMS FOR ADMINISTRATION OF MEDICAMENTS TO ANIMALS | Innozen, Inc. (US) | 2006-05-17 | — | — | EP | claimed |
| EP-1578434-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | Point Therapeutics, Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| US-20050136096-A1 | Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals | CUREX PHARMACEUTICAL MEXICO S.A.P.I. DE C.V. (MX) | 2005-06-23 | — | — | US | claimed |
| WO-2005018323-A1 | EDIBLE FILMS FOR ADMINISTRATION OF MEDICAMENTS TO ANIMALS | INNOZEN, INC. (US) | 2005-03-03 | — | — | WO | claimed |
| US-20040131628-A1 | Nucleic acids for the treatment of disorders associated with microorganisms | BRATZLER ROBERT L (US) | 2004-07-08 | — | — | US | claimed |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | POINT THERAPEUTICS, INC. | 2004-04-22 | — | — | US | claimed |
| WO-2004004658-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | POINT THERAPEUTICS, INC. (US) | 2004-01-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | BCAT1, BCAT2, APOB | KDM4E 4063/4885ALDH1A1 2720/4885HPGD 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.